Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting
Biohaven's Phase 3 trial of BHV-1300 in Graves' disease is enrolling at more than 55 sites in the US and Canada, with additional sites opening in Japan, the UK, Australia and the EU. In Phase 1b, weekly subcutaneous BHV-1300 cut pathogenic anti-TSHR-IgG1 autoantibodies by roughly 80% by week 12 and normalized free T4 and free T3 in hyperthyroid patients while sparing protective IgG3. The release also recaps October 2026's Ono Pharmaceutical deal licensing the MoDE pan-IgG portfolio in Japan, South Korea, Taiwan and ASEAN for $80 million upfront plus a $20 million milestone and ~20% royalties.
Key figures
- Drug Name
- BHV-1300
- Phase Of Trial
- Phase 3
- Trial size
- approximately 300 adults
- Ono upfront
- $80 million
- Active sites
- 55+
- Royalty rate
- approximately 20% on net sales
- Ono milestone
- $20 million
- Total igg reduction phase1
- up to 87%
- Phase1b autoantibody reduction
- ~80% by week 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.